CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.016
EU - Europa 2.725
AS - Asia 2.052
AF - Africa 20
SA - Sud America 17
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 7.852
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.988
CN - Cina 1.382
GB - Regno Unito 624
SG - Singapore 545
RU - Federazione Russa 460
FR - Francia 353
IE - Irlanda 352
SE - Svezia 250
IT - Italia 232
DE - Germania 159
UA - Ucraina 121
FI - Finlandia 102
VN - Vietnam 42
CA - Canada 24
ID - Indonesia 19
BE - Belgio 15
NL - Olanda 14
TG - Togo 14
AU - Australia 13
KR - Corea 13
IN - India 11
HK - Hong Kong 8
JP - Giappone 8
TR - Turchia 8
BR - Brasile 7
EU - Europa 7
CL - Cile 6
GR - Grecia 6
AT - Austria 5
CH - Svizzera 5
LT - Lituania 5
DK - Danimarca 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
MA - Marocco 3
AL - Albania 2
MX - Messico 2
MY - Malesia 2
SA - Arabia Saudita 2
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
ES - Italia 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 7.852
Salva come PNG Salva come JPEG
Città #
Southend 592
Chandler 569
Jacksonville 561
Singapore 458
Dublin 347
Beijing 264
Ashburn 163
Lawrence 152
Princeton 152
Wilmington 150
Jinan 130
Woodbridge 113
Nanjing 111
Shenyang 109
New York 81
Hebei 68
Houston 68
Helsinki 64
Tianjin 63
Zhengzhou 46
Sindelfingen 44
Taizhou 38
Jiaxing 37
Haikou 36
Ann Arbor 35
Dearborn 35
Redmond 35
Changsha 34
Verona 34
Grafing 33
Dong Ket 31
Ningbo 31
Guangzhou 30
Hangzhou 28
Nanchang 27
Taiyuan 27
Lanzhou 24
Norwalk 24
Seattle 24
Redwood City 20
Fuzhou 17
Milan 17
Santa Clara 17
Jakarta 15
Lomé 14
Washington 14
Boardman 13
San Francisco 13
Seoul 13
Toronto 13
Brussels 12
Dallas 10
Los Angeles 10
Bologna 9
Moscow 9
Amsterdam 7
Chicago 7
Fairfield 7
Munich 7
Falls Church 6
Frankfurt am Main 6
Lappeenranta 6
São Paulo 6
Trento 6
Vigasio 6
Canberra 5
Hong Kong 5
Kent 5
London 5
Mehlingen 5
Melbourne 5
Romola 5
Vienna 5
Arezzo 4
Berlin 4
Lisbon 4
New Delhi 4
Ottawa 4
Padova 4
Pittsburgh 4
Tokyo 4
Vicenza 4
Zurich 4
Atlanta 3
Cambridge 3
Carmignano di Brenta 3
Clearwater 3
Fremont 3
Groningen 3
Kemerovo 3
Naples 3
Nardò 3
Newark 3
Ortona 3
Rome 3
San Diego 3
Shijiazhuang 3
Trieste 3
Xiangfen 3
Aberdeen 2
Totale 5.278
Salva come PNG Salva come JPEG
Nome #
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 125
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 103
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 96
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 95
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 91
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 90
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 90
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 90
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 87
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 87
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 86
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 83
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 82
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 82
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 81
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 81
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 78
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 77
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 76
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 76
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 75
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 75
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 73
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 73
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 73
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 72
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 70
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 69
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 68
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 65
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 64
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 63
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 63
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program 63
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 61
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 60
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 60
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 60
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 60
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 60
Computerized drug management in a Bone Marrow Transplant Unit: towards an improvement of hospital drug management 59
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 59
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 59
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 59
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 59
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 59
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? 58
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 57
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 57
Bendamustine plus rituximab: is it a BRIGHT idea? 57
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 56
Computer-based drug management in a bone marrow transplant unit:a suitable tool for multiple prescriptions even in critical conditions 55
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia 55
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 55
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 54
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 53
P53 and p21waf1 expression by immunohistochemistry in diffuse large B-cell lymphoma has a strong and independent impact on survival of patients with germinal center phenotype 53
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 53
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 53
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 53
Autoimmune cytopenias in chronic lymphocytic leukemia 53
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 52
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 52
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 51
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 51
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 51
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 50
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 50
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 49
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 49
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 48
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma 47
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 47
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL 47
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 47
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 46
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 46
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma 45
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 45
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 44
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 44
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma 43
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 43
Genetic and phenotypic attributes of splenic marginal zone lymphoma 43
Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma 43
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 42
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program 42
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 42
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 42
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 42
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 42
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and {CAR}-T Cell Therapy 42
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP 41
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 41
Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination? 41
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 41
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 41
The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment 41
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 40
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement 40
Totale 6.012
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.080
article - articoli 36.550
book - libri 0
conference - conferenze 1.530
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.160
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020630 0 0 0 0 0 132 36 106 30 88 72 166
2020/20211.256 166 223 29 270 142 166 6 18 24 20 139 53
2021/2022915 52 197 17 44 35 27 46 64 35 29 58 311
2022/20231.992 168 170 210 271 186 523 31 114 214 18 49 38
2023/20241.080 38 93 82 103 99 215 50 106 12 33 174 75
2024/20251.301 204 188 87 571 132 119 0 0 0 0 0 0
Totale 8.052